ARCA hires Cole as VP of investor relations, communications
ARCA biopharma, a biopharmaceutical developer of genetically targeted therapies for heart failure and other cardiovascular diseases, has appointed Derek Cole as vice president (VP), investor relations and corporate communications, effective immediately.
The Broomfield, Colo.-based company said that Cole will be responsible for the creation and implementation of strategic communications efforts that support ARCA’s business objectives to stakeholders, including the investment community, media and employees. He will report directly to Richard B. Brewer, president and CEO of ARCA.
Previously, Cole served as VP, investor relations and corporate communications for Allos Therapeutics. Before joining Allos, he headed the investor relations and corporate communications function at Myogen, a therapeutics company focused on cardiovascular disease until its sale in November 2006. He is also on the board of directors and board executive committee of the Colorado BioScience Association.
The Broomfield, Colo.-based company said that Cole will be responsible for the creation and implementation of strategic communications efforts that support ARCA’s business objectives to stakeholders, including the investment community, media and employees. He will report directly to Richard B. Brewer, president and CEO of ARCA.
Previously, Cole served as VP, investor relations and corporate communications for Allos Therapeutics. Before joining Allos, he headed the investor relations and corporate communications function at Myogen, a therapeutics company focused on cardiovascular disease until its sale in November 2006. He is also on the board of directors and board executive committee of the Colorado BioScience Association.